

Wan-Teck Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4624122/publications.pdf>

Version: 2024-02-01

172
papers

9,515
citations

50244

46
h-index

40954

93
g-index

184
all docs

184
docs citations

184
times ranked

15124
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 989-998.	2.0	5
2	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	0.5	114
3	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 625-634.	1.9	4
4	Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment. <i>Cancer Communications</i> , 2022, , .	3.7	3
5	Prognostic Neurotransmitter Receptors Genes Are Associated with Immune Response, Inflammation and Cancer Hallmarks in Brain Tumors. <i>Cancers</i> , 2022, 14, 2544.	1.7	8
6	MicroRNA-Profilng Based Screening of Non-small-cell Lung Cancer in Plasma. , 2021, , 295-306.		1
7	Phase II study of nimotuzumab (TheraCim®) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 1641-1651.	0.9	7
8	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	1.0	2
9	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. <i>Oral Oncology</i> , 2021, 115, 105222.	0.8	11
10	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. <i>Lung Cancer</i> , 2021, 155, 127-135.	0.9	6
11	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021, 5, 859-875.	1.5	4
12	JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA2-LBA2.	0.8	21
13	Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report. <i>Translational Lung Cancer Research</i> , 2021, 10, 2298-2305.	1.3	0
14	Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698551.	1.3	9
15	Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 5939-5950.	3.2	21
16	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
17	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	15.2	197
18	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6413-6423.	3.2	37

#	ARTICLE	IF	CITATIONS
19	Bacillus Calmette-Guérin scar flare after an mRNA SARS-CoV-2 vaccine. <i>Cmaj</i> , 2021, 193, E1178-E1178.	0.9	5
20	Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 657-663.	0.7	12
21	Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2131892.	2.8	25
22	Prognostic Matrisomal Gene Panel and Its Association with Immune Cell Infiltration in Head and Neck Carcinomas. <i>Cancers</i> , 2021, 13, 5761.	1.7	4
23	The case for better hospitalisation selection in cancer patients. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 880-881.	0.2	0
24	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	0.9	79
25	Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. <i>Journal of Medical Economics</i> , 2020, 23, 1330-1339.	1.0	11
26	Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1928-1934.	0.5	30
27	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 1254-1262.	2.4	19
28	Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. <i>Cancers</i> , 2020, 12, 1025.	1.7	30
29	Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. <i>Annals of Oncology</i> , 2020, 31, 789-797.	0.6	62
30	Genomic landscape of lung adenocarcinoma in East Asians. <i>Nature Genetics</i> , 2020, 52, 177-186.	9.4	281
31	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
32	Abstract CT203: A phase II trial of ipilimumab in combination with nivolumab in EBV-associated advanced nasopharyngeal carcinoma (NCT03097939). <i>Cancer Research</i> , 2020, 80, CT203-CT203.	0.4	2
33	Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC). , 2020, , .		3
34	Abstract 5060: Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy. , 2020, , .		0
35	Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins. <i>Translational Lung Cancer Research</i> , 2020, 9, 2302-2304.	1.3	2
36	Compendiums of cancer transcriptomes for machine learning applications. <i>Scientific Data</i> , 2019, 6, 194.	2.4	13

#	ARTICLE	IF	CITATIONS
37	Matrisomal abnormality: a predictive biomarker for cancer immunotherapy. <i>Annals of Oncology</i> , 2019, 30, vi103.	0.6	1
38	Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. <i>Cancers</i> , 2019, 11, 1595.	1.7	53
39	Liquid biopsy: one cell at a time. <i>Npj Precision Oncology</i> , 2019, 3, 23.	2.3	72
40	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. <i>PLoS ONE</i> , 2019, 14, e0221305.	1.1	14
41	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	2.3	58
42	Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients. <i>Annals of Oncology</i> , 2019, 30, ii54.	0.6	0
43	Bright Aggregation-Induced Emission Dots for Dynamic Tracking and Grading of Patient-Derived Xenografts in Zebrafish. <i>Advanced Functional Materials</i> , 2019, 29, 1901226.	7.8	19
44	Methionine is a metabolic dependency of tumor-initiating cells. <i>Nature Medicine</i> , 2019, 25, 825-837.	15.2	226
45	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the "real-world" clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983637.	1.4	25
46	IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. <i>Annals of Oncology</i> , 2019, 30, ii48-ii49.	0.6	7
47	Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 876-884.	0.8	91
48	Addressing cellular heterogeneity in tumor and circulation for refined prognostication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17957-17962.	3.3	51
49	P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, S609-S610.	0.5	8
50	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). <i>PLoS ONE</i> , 2019, 14, e0224665.	1.1	17
51	Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC). <i>Cancer Research</i> , 2019, 79, CT150-CT150.	0.4	15
52	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9124-TPS9124.	0.8	11
53	Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. <i>Nature Communications</i> , 2018, 9, 216.	5.8	136
54	Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 532-542.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. <i>BMC Cancer</i> , 2018, 18, 352.	1.1	16
56	A Decade of Never-smokers Among Lung Cancer Patients: Increasing Trend and Improved Survival. <i>Clinical Lung Cancer</i> , 2018, 19, e539-e550.	1.1	21
57	Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. <i>Annals of Oncology</i> , 2018, 29, ix161.	0.6	5
58	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , 2018, 36, 1412-1418.	0.8	324
59	Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. <i>Annals of Oncology</i> , 2018, 29, viii525.	0.6	3
60	Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma. <i>Annals of Oncology</i> , 2018, 29, viii678.	0.6	2
61	A merged lung cancer transcriptome dataset for clinical predictive modeling. <i>Scientific Data</i> , 2018, 5, 180136.	2.4	25
62	P2.13-21 MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S806.	0.5	0
63	IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. <i>Annals of Oncology</i> , 2018, 29, ix177-ix178.	0.6	7
64	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. <i>BMC Cancer</i> , 2018, 18, 1198.	1.1	18
65	P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers. <i>Journal of Thoracic Oncology</i> , 2018, 13, S463.	0.5	2
66	Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. <i>Nature</i> , 2018, 557, 575-579.	13.7	942
67	Primary pulmonary lymphoepithelioma-like carcinoma in Singapore. <i>Annals of Thoracic Medicine</i> , 2018, 13, 30.	0.7	22
68	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	0.8	345
69	EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 529-538.	0.5	57
70	Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 120-123.	0.7	3
71	Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 255-273.	0.8	12
72	Metronomic chemotherapy: A relook at its basis and rationale. <i>Cancer Letters</i> , 2017, 388, 328-333.	3.2	10

#	ARTICLE	IF	CITATIONS
73	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). <i>Annals of Oncology</i> , 2017, 28, 2698-2706.	0.6	77
74	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. <i>Nature Medicine</i> , 2017, 23, 1167-1175.	15.2	141
75	P3.01-017 Clinical Outcomes of Patients with EGFR T790M + NSCLC on Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2206.	0.5	0
76	MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1847-S1848.	0.5	4
77	A phase I pharmacokinetic study of metronomic vinorelbine and sorafenib using two schedules in Asian non-small cell lung cancer (NSCLC) patients. <i>Annals of Oncology</i> , 2017, 28, x39-x40.	0.6	0
78	An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. <i>Nature Communications</i> , 2017, 8, 1734.	5.8	95
79	EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs). <i>Annals of Oncology</i> , 2017, 28, x127-x128.	0.6	0
80	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486.	0.8	13
81	Comparing genomic landscape of early stage, treatment naïve and late stage, drug resistant EGFR-mutant lung adenocarcinomas. <i>Canadian Journal of Biotechnology</i> , 2017, 1, 246-247.	0.3	0
82	Concordance of anaplastic lymphoma kinase (<i>ALK</i>) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 23251-23262.	0.8	61
83	MINIO1.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S257-S258.	0.5	11
84	Clinical outcome of reflex EGFR mutation and ALK fusion testing in patients with non-squamous non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 75-80.	0.7	0
85	Novel therapeutic targets on the horizon for lung cancer. <i>Lancet Oncology</i> , The, 2016, 17, e347-e362.	5.1	156
86	Treatment and outcomes of elderly patients (>65 years) with lung adenocarcinoma. <i>European Journal of Cancer</i> , 2016, 60, e17.	1.3	0
87	Microfluidic enrichment for the single cell analysis of circulating tumor cells. <i>Scientific Reports</i> , 2016, 6, 22076.	1.6	109
88	Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. <i>Nature Communications</i> , 2016, 7, 11702.	5.8	155
89	Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9067-9067.	0.8	41
90	Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. <i>PLoS ONE</i> , 2016, 11, e0154316.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Advances in systemic treatment for nasopharyngeal carcinoma. Chinese Clinical Oncology, 2016, 5, 21-21.	0.4	69
92	Molecular detection of ROS1-rearranged circulating tumor cells (CTC) in non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2016, 34, e23086-e23086.	0.8	1
93	Abstract 5008: Elucidating HER2 molecular heterogeneity of circulating tumor cells among breast cancer patients. , 2016, , .		0
94	Concordance of ALK rearrangement patterns between CTCs and tumour in non-small cell lung cancer (NSCLC). Annals of Oncology, 2015, 26, vii113.	0.6	0
95	Life-Threatening Pneumonitis Related to Docetaxel Chemotherapy. Proceedings of Singapore Healthcare, 2015, 24, 54-58.	0.2	2
96	Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer, 2015, 121, 1599-1607.	2.0	163
97	Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer, 2015, 88, 289-296.	0.9	16
98	Do elderly patients benefit from enrollment into Phase I Trials?. Journal of Geriatric Oncology, 2015, 6, 241-248.	0.5	4
99	Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 91, 952-960.	0.4	197
100	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Investigational New Drugs, 2015, 33, 985-991.	1.2	31
101	Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer. Head and Neck, 2015, 37, 1349-1357.	0.9	7
102	Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. Head and Neck, 2015, 37, 1650-1659.	0.9	9
103	Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS ONE, 2015, 10, e0123587.	1.1	30
104	Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Molecular Cancer Therapeutics, 2015, 14, A46-A46.	1.9	3
105	Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. PLoS ONE, 2014, 9, e99409.	1.1	165
106	Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma. Molecular Therapy, 2014, 22, 132-139.	3.7	185
107	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1578-1584.	0.6	10
108	Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. International Journal of Cancer, 2014, 135, 1092-1100.	2.3	41

#	ARTICLE	IF	CITATIONS
109	Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab on A Chip, 2014, 14, 128-137.	3.1	485
110	Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. Molecular Cancer, 2014, 13, 13.	7.9	42
111	Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC): Asian subgroup analysis. Annals of Oncology, 2014, 25, 529-536.	0.6	26
112	HPV-associated lung cancers: an international pooled analysis. Carcinogenesis, 2014, 35, 1267-1275.	1.3	57
113	An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. Analyst, The, 2014, 139, 3245-3255.	1.7	173
114	Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. Nature Medicine, 2014, 20, 1090-1091.	15.2	8
115	Ultra-High Throughput Enrichment of Viable Circulating Tumor Cells. IFMBE Proceedings, 2014, , 1-4.	0.2	2
116	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. Journal of Clinical Oncology, 2014, 32, 2520-2520.	0.8	31
117	Randomized phase III trial of concurrent chemoradiation with or without neoadjuvant gemcitabine, carboplatin, and paclitaxel in locally advanced nasopharyngeal cancer.. Journal of Clinical Oncology, 2014, 32, 6003-6003.	0.8	5
118	Phase Ib/II study of the PI3K± inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).. Journal of Clinical Oncology, 2014, 32, 6044-6044.	0.8	16
119	Targeting <i>FGFR1</i>-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.. Journal of Clinical Oncology, 2014, 32, 8034-8034.	0.8	27
120	Phase I dose escalation study of pan-histone deacetylase (HDAC) inhibitor abexinostat in combination with cisplatin in patients with advanced non-keratinizing nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2014, 32, e17059-e17059.	0.8	0
121	Relationship between tumor response with outcomes in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKI).. Journal of Clinical Oncology, 2014, 32, e19101-e19101.	0.8	0
122	Differences in clinical characteristics and overall survival in never-smokers with lung squamous cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e12527-e12527.	0.8	0
123	Isolation and retrieval of circulating tumor cells using centrifugal forces. Scientific Reports, 2013, 3, 1259.	1.6	618
124	Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary. Journal of Clinical Oncology, 2013, 31, e237-e239.	0.8	31
125	Do elderly patients benefit from enrollment in phase I clinical trials?. Journal of Clinical Oncology, 2013, 31, 9509-9509.	0.8	1
126	Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of Oncology, 2012, 23, 1010-1016.	0.6	20

#	ARTICLE	IF	CITATIONS
127	A phase II study evaluating the safety and efficacy of an adenovirus- β -LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2012, 23, 997-1005.	0.6	110
128	Dynamic Contrast-Enhanced Computed Tomography in Metastatic Nasopharyngeal Carcinoma. <i>Investigative Radiology</i> , 2012, 47, 5-10.	3.5	7
129	A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3179-3184.	1.8	148
130	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. <i>Nature Medicine</i> , 2012, 18, 521-528.	15.2	510
131	Influence of <i>SLCO1B3</i> haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 606-618.	1.1	30
132	Abstract 1911: A common BIM polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. , 2012, , .		0
133	Docetaxel pharmacogenetics: The influence of <i>RXRα</i> and <i>HNF4α</i> genetic variations on docetaxel disposition in Asian nasopharyngeal carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2598-2598.	0.8	0
134	Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. <i>Bone Marrow Transplantation</i> , 2011, 46, 573-579.	1.3	8
135	The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1471-1478.	1.1	67
136	'Prechronous' metastasis in clear cell renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 181.	0.4	3
137	Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 3542-3550.	3.2	65
138	Fanconi's Anemia in Adulthood: Chemoradiation-Induced Bone Marrow Failure and a Novel FANCA Mutation Identified by Targeted Deep Sequencing. <i>Journal of Clinical Oncology</i> , 2011, 29, e591-e594.	0.8	15
139	A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 5481-5489.	3.2	96
140	Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2011, 22, 718-722.	0.6	64
141	Hemoglobin subunit beta (HBB) is a potential biomarker for predicting response to Gefitinib in NSCLC patients. <i>Journal of Integrated OMICS</i> , 2011, 1, .	0.5	0
142	Correlation between Epidermal Growth Factor Receptor Mutations and Expression of Female Hormone Receptors in East-Asian Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2010, 5, 17-22.	0.5	35
143	Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. <i>Biosensors and Bioelectronics</i> , 2010, 26, 1701-1705.	5.3	191
144	Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 53-60.	2.0	27

#	ARTICLE	IF	CITATIONS
145	Nonmyeloablative Allogeneic Stem Cell Transplantation for Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2010, 15, 1192-1197.	1.9	1
146	Phase II clinical trials in oncology: are we hitting the target?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 427-438.	1.1	7
147	Truth About ERCC1 in Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, e162-e162.	0.8	3
148	Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol [®] -PM) in patients with solid tumors. <i>Annals of Oncology</i> , 2010, 21, 382-388.	0.6	119
149	A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 67, 325-329.	0.9	7
150	Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. <i>Oncology Reports</i> , 2009, 21, 971-5.	1.2	25
151	Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. <i>Journal of Thoracic Oncology</i> , 2009, 4, 988-993.	0.5	3
152	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1102-1110.	5.1	28
153	Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2008, 113, 1332-1337.	2.0	58
154	A Phase I trial of weekly docetaxel and topotecan for solid tumors. <i>Acta Oncologica</i> , 2008, 47, 311-315.	0.8	1
155	Induction concurrent chemoradiotherapy using Paclitaxel and Carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer-Asian experience. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 377-82.	0.2	2
156	Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer. <i>Acta Oncologica</i> , 2007, 46, 1032-1034.	0.8	8
157	A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly. <i>Journal of Thoracic Oncology</i> , 2007, 2, 230-236.	0.5	54
158	Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. <i>Lung Cancer</i> , 2007, 56, 161-166.	0.9	26
159	Pharmacogenetics of Target Genes Across the Warfarin Pharmacological Pathway. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1189-1200.	1.6	27
160	A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. <i>Oncology Reports</i> , 2006, 15, 123.	1.2	1
161	Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. <i>International Journal of Dermatology</i> , 2006, 45, 1093-1095.	0.5	13
162	Lung cancer in never-smokers. <i>Journal of Clinical Pathology</i> , 2006, 60, 337-340.	1.0	39

#	ARTICLE	IF	CITATIONS
163	Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. <i>Journal of Clinical Oncology</i> , 2006, 24, 2245-2251.	0.8	334
164	Electroacupuncture for Refractory Acute Emesis Caused by Chemotherapy. <i>Journal of Alternative and Complementary Medicine</i> , 2006, 12, 963-969.	2.1	21
165	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. <i>British Journal of Cancer</i> , 2005, 93, 23-28.	2.9	50
166	Adrenal Insufficiency in Intestinal Obstruction from Carcinomatosis Peritonei—A Factor of Potential Importance in Symptom Palliation. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 411-418.	0.6	3
167	Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2005, 103, 569-575.	2.0	77
168	Variable Problems in Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 8112-8113.	0.8	5
169	Should Screening for DPD Deficiency Be Mandatory before 5-FU Exposure?. <i>Oncology Research and Treatment</i> , 2004, 27, 531-533.	0.8	4
170	The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-small Cell Lung Cancer. <i>Chest</i> , 2004, 126, 1750-1756.	0.4	127
171	Profiling Circulating Tumour Cells for Clinical Applications. , 0, , .		0
172	JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0